Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

The Future of Targeted Therapy in Rheumatology: Biologics or Small Molecules?

Published: Tuesday, August 12, 2014
Last Updated: Tuesday, August 12, 2014
Bookmark and Share
While biologics can modulate extracellular protein-protein interactions, intracellular processes can be more effectively targeted by small molecules.

Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the molecular mechanisms involved. That approach changed with the introduction of biologic therapeutics at the end of the 20th century and by the recent development of small-molecule inhibitors of intracellular signal transduction pathways. Here we compare and discuss the advantages and disadvantages of those two groups of targeted anti-inflammatory therapeutics.

TNF-blocking biologic agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s. Further biologic agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy. During the last few years, another wave of novel discoveries led to the development of a new class of small molecule anti-inflammatory compounds targeting intracellular signal transduction molecules, such as tyrosine kinases. In all those cases, the specific targets of the drugs are well defined and significant knowledge about their role in the disease pathomechanism is available, qualifying them for being targeted therapeutics for inflammatory rheumatic diseases. While both groups of targeted therapeutics offer significant clinical benefit, they clearly differ in several aspects, such as the localization of their targets, their route of administration and target specificity, as well as technical details such as manufacturing procedures and cost basis. In this debate paper, we compare the advantages and disadvantages of the two different approaches, aiming to shed light on the possible future of targeted therapies.

Biologic therapeutics and small-molecule inhibitors both have significant advantages and disadvantages in the therapy of rheumatic diseases. The future of targeted therapies is one of the most exciting questions of current rheumatology research and therapy.

The article, What is the future of targeted therapy in rheumatology: biologics or small molecules? is published online in the journal BMC Medicine and is free to access.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Separation of mAbs Molecular Variants by Analytical HIC-HPLC
HIC-HPLC is a less widely used analytical technique compared with standard methods for separating variants based on size, charge or electrophoretic mobility.
Thursday, June 05, 2014
Evaporative Light Scattering Detection Based HPLC Method for the Determination of Polysorbate 80 in Therapeutic Protein Formulations
The suitability of the new method has been evaluated by testing its specificity, linearity, precision, sensitivity and accuracy.
Wednesday, March 13, 2013
Identifying Mechanism-of-Action Targets for Drugs and Probes
A chemical information approach to drug-target association can guide therapeutic development and reveal applications to probe biology.
Friday, July 06, 2012
Algae-Produced Surface Protein Elicits Antibodies That Inhibit Malaria Transmission
In this study, scientists tested whether algal chloroplasts can produce malaria transmission blocking vaccine candidates, Plasmodium falciparum surface protein 25 (Pfs25) and 28 (Pfs28).
Thursday, May 24, 2012
Analysis of Host-Cell Proteins in Biotherapeutic Proteins by Comprehensive Online Two-Dimensional Liquid Chromatography/Mass Spectrometry
This paper presents assays for identification and quantification of host-cell proteins in biotherapeutic proteins over 5 orders of magnitude in concentration.
Friday, March 02, 2012
Towards Protein Crystallization as a Process Step in Downstream Processing of Therapeutic Antibodies: Screening and Optimization at Microbatch Scale
Researchers from Biberach University of Applied Sciences demonstrate that crystallization has the potential to be included in downstream processing as a low-cost purification or formulation step.
Monday, October 17, 2011
Mutagenesis of SP-D Informed by Evolution and Xray Crystallography Enhances Defenses Against Influenza A Virus In Vivo
These studies demonstrate the potential utility of homology modeling and protein structure analysis for engineering effective collectin antivirals as in vivo therapeutics.
Monday, October 17, 2011
Development of a Rapid Process Monitoring Method for Dry-Coated Tableting Process by Using Near-Infrared Spectroscopy
Researchers have developed a nondestructive transmittance near-infrared (NIR) method for detecting off-centered cores in dry-coated (DC) tablets as a monitoring system in the DC tableting process.
Thursday, August 04, 2011
Novel Therapeutic Strategies for Targeting Liver Cancer Stem Cells
A review article published in the International Journal of Biological Sciences provides a brief review of molecular signaling in liver CSCs and present insights into new therapeutic strategies for targeting liver CSCs.
Thursday, May 12, 2011
Evaluating the Efficacy of Sequential Biologic Therapies for Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor-Alpha Inhibitors
A provisional article published in Arthritis Research and Therapy systematically reviews and quantitatively evaluates the relationship between clinical response to biologic treatments and number of previous treatments with tumor necrosis factor-alpha (TNF-alpha) inhibitors.
Thursday, February 17, 2011
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos